From: Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study
Variable | Pre-protocol | Post-protocol | P |
---|---|---|---|
Correct inhaler technique | 23 (63.9) | 31 (86.1) | 0.008 |
Fully adherent to treatment | 2 (5.6) | 34 (94.4) | N/A |
Rhinitis score | 8 (0–18) | 5 (0–15) | 0.001 |
Asthma Control Test score | 16.5 (6–25) | 22.5 (8–25) | 0.002 |
Posology and medications in use | |||
Leukotriene receptor antagonists | 4 (11.1) | 12 (33.3) | 0.008 |
Omalizumab | 0 (0) | 1 (2.7) | N/A |
Continuous oral ICS | 3 (8.3) | 8 (22.2) | 0.063 |
Equivalent dose of budesonide (μg) | 800 (800–1200) | 800 (800–1600) | 0.059 |
Well-controlled home environment | 9 (25) | 15 (41.7) | 0.109 |
Psychiatric disorder | 3 (8.3) | 8 (22.2) | 0.125 |
Number of exacerbations | 4 (0–20) | 2 (0–11) | 0.006 |
Sputum cytologyc | |||
Eosinophils (%) | 2.0 (0–37) | 1.1 (0–49) | 0.948 |
Eosinophils ≥ 2.5% | 9 (25.0) | 9 (25.0) | 0.362 |
Neutrophils > 54% | 4 (17.4) | 6 (18.8) | 0.114 |
Pre-BD FEV1 (%) | 77.0 (36–113) | 78.7 (31–113) | 0.038 |
Pre-BD FEV1/FVC ratio (%) | 78.0 (53–100) | 80.0 (43–95) | 0.417 |
Pre-BD FE 25–75% (%) | 61.0 (16–131) | 66.5 (15–110) | 0.156 |
Post-BD variation in FEV1 (%) | 11.0 (0–70) | 5.0 (0–45) | 0.004 |
Post-BD variation in FEF25–75% (%) | 31.0 (0.0–166.0) | 14.0 (0.0–96.0) | 0.013 |
FeNO (ppb) | 31 (5–125) | 14 (0–112) | 0.016 |